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Abstract
Background: IL-13 has been implicated in the development of airway inflammation and hyperresponsiveness. This
study investigated the multiple-dose pharmacokinetics and safety profile of human anti-IL-13 antibody (CAT-354) in
adults with asthma.
Methods: This was a multiple-dose, randomised, double-blind, placebo-controlled phase 1 study in asthmatics
(forced expiratory volume in 1 second [FEV1] ≥ 80% predicted). Subjects were randomised to receive three
intravenous infusions of CAT-354 (1 mg/kg, 5 mg/kg or 10 mg/kg) or placebo at 28-day intervals. Blood samples
were taken for pharmacokinetic measurements. Safety was assessed by adverse events, vital signs, ECGs, laboratory
and pulmonary function parameters.
Results: Twenty-three subjects (aged 21-60 years, FEV1 88-95% predicted) received ≥ 1 dose of study medication.
The half-life of CAT-354 was 12-17 days and was dose-independent. The maximum serum concentration and area
under the curve were dose-dependent. Clearance (2.2-2.6 mL/day/kg) and volume of distribution (44-57 mL/kg)
were both low and dose-independent. The observed maximum serum concentration after each dose increased
slightly from dose 1 through dose 3 at all dose levels, consistent with an accumulation ratio of 1.4 to 1.7 for area
under the curve. Most adverse events were deemed mild to moderate and unrelated to study medication. One
SAE was reported and deemed unrelated to study drug. There were no effects of clinical concern for vital signs,
ECG, laboratory or pulmonary parameters.
Conclusions: CAT-354 exhibited linear pharmacokinetics and an acceptable safety profile. These findings suggest
that at the doses tested, CAT-354 can be safely administered in multiple doses to patients with asthma.
Trial registration: NCT00974675.
Background
Asthma is characterised by variable airflow obstruction
and airway hyperresponsiveness (AHR) in association
with airway inflammation [1]. Inhaled corticosteroids
(ICS) are currently the first-line anti-inflammatory treat-
ment for persistent asthma [1]. However, many asthma
patients remain symptomatic despite ICS therapy [2,3].
Alternative anti-inflammatory therapies are needed in
asthma.
T helper-2 (TH-2) lymphocytes release cytokines,
including IL-4, IL-5 and IL-13, that have a range of
actions, including eosinophil activation and immunoglo-
bulin secretion from B cells. Clinical studies have shown
that asthma is associated with TH-2 inflammation [4-6].
Targeting the cytokines involved in TH-2 inflammation
may therefore be an effective therapeutic strategy.
IL-13 levels are increased in the airways of patients
with asthma [7,8]. Of particular importance is the find-
ing that IL-13 positive cells are present within the air-
way smooth muscle and expressed predominantly by
mast cells, suggesting that IL-13 plays a pivotal role in
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mast cell-airway smooth muscle interactions [9]. The
genes encoding for IL-13 and IL-4 are both located on
the cytokine cluster on chromosome 5q31. These TH-2
cytokines share some structural similarities, and both
exert their actions through the IL-4Ra/IL-13Ra1 recep-
tor complex; therefore, these cytokines have overlapping
functions. IL-4 also exerts independent effects through
the IL-4Ra/g receptor. However, animal models suggest
a dominant role for IL-13 in the pathophysiology of
allergic inflammation, as IL-13 causes AHR, eosinophilic
inflammation and mucus hypersecretion [10-14]. Antag-
onising the function of IL-13 in asthma may be a thera-
peutically effective strategy.
CAT-354 is a high affinity, human monoclonal IgG4
antibody that specifically binds to and neutralises IL-13.
This study aimed to assess the pharmacokinetics, toler-
ability and safety of repeated doses of CAT-354 in sub-
jects with mild to moderate asthma.
Methods
Subject eligibility
This study was conducted at two UK sites: the Medi-
cines Evaluation Unit and the Chiltern clinical research
unit. Ethics approval was obtained at both sites and the
study was conducted in accordance with ICH Good
Clinical Practice guidelines and in compliance with the
2000 Declaration of Helsinki. All subjects provided writ-
ten informed consent prior to the performance of any
study-specific procedures.
Subjects aged 18 to 60 years with a physician diagno-
sis of asthma were eligible to participate in this study.
Female subjects were either postmenopausal (no men-
strual period for a minimum of 1 year) or surgically
sterilised. Subjects had to have a forced expiratory
volume in 1 second (FEV1) of ≥ 80% of predicted nor-
mal and be well controlled on ICS and short-acting b2-
agonists (SABA) only with no change in the dose of ICS
for 3 months prior to the study. Subjects were also
required to not have smoked in the previous year and
have a smoking history of ≤ 10 pack years.
Exclusion criteria were an asthma exacerbation requir-
ing hospitalisation within 3 years of the study, a history
of any active disease other than eczema, seasonal allergy
which was expected to start before the last dose of
study material, poorly controlled asthma defined as
SABA > 6 times/day on any one day or > 3 times/day
on six or more days within the 2 weeks prior to the
study, previous treatment with any other asthma medi-
cations within 6 months of the study, treatment for ato-
pic symptoms except eczema within the previous 4
weeks, any acute illness in the prior 2 weeks, a lower
respiratory tract infection within 4 weeks, previous
treatment with a monoclonal antibody or related protein
and participation in another study within 3 months (or
5 half-lives of the investigational product). Participants
had to have a medical history negative for alcohol or
substance abuse and no clinically significant ECG or
clinical chemistry, haematology or urinalysis result.
Study design
The study was a double-blind, randomised, placebo-con-
trolled phase 1 study. Subjects attended the clinic for 13
visits over a 147-day study period (Figure 1). Subjects
had a screening visit up to 28 days prior to randomisa-
tion. Study eligibility was confirmed at the randomisa-
tion visit, at which subjects were randomised to receive
CAT-354 or placebo in addition to their usual medica-
tion (ICS and SABA). Subjects were recruited sequen-
tially to one of three dose groups and randomised
within each dose group to receive either CAT-354
(1 mg/kg, 5 mg/kg or 10 mg/kg) or placebo. Within
each group, randomisation to CAT-354 or placebo was
in a ratio of 4:1, respectively. CAT-354 was formulated
at a nominal concentration of 10 mg/mL in phosphate-
buffered saline (MedImmune). The placebo solution,
phosphate-buffered saline, was supplied in matching
vials. Study treatment was administered by 30-minute
intravenous infusion at each of these visits using a syr-
inge pump. Each subject received three doses of the
assigned treatment, administered with a 28-day interval
between doses. As a safety precaution, the first 3 sub-
jects within each dose group were administered CAT-
354 with at least 24 hours between subjects. Follow up
for pharmacokinetic blood sampling and safety observa-
tions continued up to day 147 after the first dose (91
days after the third dose).
Study procedures
Pharmacokinetic assessments
Serum samples for pharmacokinetic assessments were
obtained pre-dose and at 10 minutes and 12 hours after
the infusion on dosing days. Single samples were also
collected at all other visits. Serum concentrations of
CAT-354 and anti-CAT-354 were assessed by MedIm-
mune using a quantitative sandwich ELISA based immu-
noassay performed on the Gyrolab assay platform. This
method exhibits accuracy of ≤ 25% absolute relative
error and precision of ≤ 20% coefficient of variation
with a lower limit of quantification of 0.300 μg/mL.
Safety assessments
Safety was assessed by monitoring the occurrence of
adverse events or abnormalities identified by standard
laboratory tests, vital sign measurements, physical exam-
inations and ECGs. Laboratory tests were performed at
screening and 7 days after administration of each dose
and the end of the study. Samples for urinalysis were
collected at screening and the end of the study only, as
were physical examinations. Vital signs were taken at
screening and on dosing days pre-dose and prior to dis-
charge after each dose and at the end of the study.
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ECGs were performed at the screening visit, within 6-7
hours after the first dose and at the end of the study.
Immunogenicity evaluations
To assess any immunogenic response, blood samples of
all subjects taken pre-dose and at the last clinic visit
were tested for the presence of anti-CAT-354 antibodies
using a double-bridging ELISA assay [15] with a sensi-
tivity of 1 μg/mL for the detection of an anti-idiotypic
monoclonal antibody standard against CAT-354.
Immuno-inhibition by CAT-354 and an isotype matched
control antibody as an additional confirmatory assay was
performed to eliminate false positive results.
Lung function assessments
FEV1, forced vital capacity (FVC) and the FEV1/FVC
ratio were measured using a standardised, calibrated spi-
rometer at each visit. At dosing visits, lung function was
measured pre-dose and 30 minutes and 12 hours after
the infusion. Wherever possible, pulmonary function
tests were recorded at the same time of day.
Statistical analysis
It was planned that eight subjects per dose group were
to be evaluated for CAT-354. In addition, it was planned
that a minimal number of subjects (6 in total) were to
be allocated to placebo as a control for the assessment
of tolerability (giving an overall ratio of 4:1 active:con-
trol). Cohorts of this size are considered to be adequate
to provide the information required to fulfill the objec-
tives of the study whilst exposing a minimum number
of subjects to investigational product [16].
All safety and tolerability assessments were based on
the safety population, defined as all subjects who
received at least one dose of study material. No formal
statistical testing was performed on safety data due to
the exploratory nature of the study. The pharmacoki-
netic population was defined as all subjects in the safety
population for whom sufficient post-dose blood samples
were taken to estimate the observed maximum concen-
tration (Cmax) and was used for pharmacokinetic para-
meter estimates. The pharmacokinetic parameters were
estimated for each subject using WinNonlin software
(Pharsight Corporation, California, version 5). Non-com-
partmental analysis was performed to generate para-
meter estimates using model 202 (intravenous infusion).
The elimination phase volume of distribution (Vd) was
calculated from clearance and the elimination rate
constant.
Results
Demographics and baseline characteristics
Due to the slow recruitment rate, the study was closed
before the planned number of subjects was achieved in
the highest dose group (10 mg/kg). A total of 23 sub-
jects (22 male, 1 female) were randomised and included
in the safety population. An additional 23 subjects were
screened but were not eligible for the study (Figure 2).
Of the 23 subjects included in the safety population, 19
subjects were also included in the pharmacokinetic
population. Four subjects received placebo and were
therefore not included in the pharmacokinetic popula-
tion. Baseline characteristics of the safety population are
shown in Table 1. All subjects had at least a 1-year his-
tory of asthma and were using ICS (mean overall beclo-
methasone dipropionate dose, 400 μg/day; range, 100-
1000 μg/day) and SABA only.
Pharmacokinetics
Of the 19 subjects in the pharmacokinetic population, 5
did not complete the study and receive all three doses
of CAT-354 (Figure 2). The full range of pharmacoki-
netic parameters could therefore only be derived for the
14 subjects who received all three doses. The serum
concentration-time profiles for each dosing group are
shown in Figure 3.
After a single dose, the half-life was 12-17 days and
independent of dose level. Serum concentrations were
still well above the limit of quantification by 28 days,
when the next dose was given. Serum concentrations for
the second and third doses generally increased at all
time points.
Dose proportional increases in Cmax, AUC(0-t) and
AUC(0-inf) were observed after a single dose (Table 2).
Figure 1 Schedule of study visits.
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Figure 2 Flowchart of subjects through the study.
Table 1 Baseline characteristics of the safety population
Anti-IL-13
1 mg/kg (n = 8) 5 mg/kg (n = 8) 10 mg/kg (n = 3) Placebo (n = 4)
Randomised, n 8 8 3 4
Completed study, n (%) 6 (75.0) 7 (87.5) 1 (33.3) 2 (50.0)
Sex, n (%)
Male 8 (100) 8 (100) 2 (66.6) 4 (100)
Female 0 0 1 (33.3) 0
Age, years
Mean (SD) 39.4 (9.1) 34.6 (7.6) 43.3 (14.5) 40.0 (13.0)
Range 26-54 21-46 34-60 26-53
Race, n (%)
White 8 (100) 7 (87.5) 3 (100) 4 (100)
Black 0 1 (12.5) 0 0
Weight, kg
Mean (SD) 78.5 (11.2) 88.3 (17.3) 78.3 (20.7) 76.0 (9.8)
BMI, kg/m2
Mean (SD) 24.6 (3.0) 26.3 (4.3) 27.3 (3.1) 23 (3.0)
% predicted FEV1
Mean (SD) 95.3 (8.3) 95.5 (9.8) 90.7 (9.5) 88.8 (4.6)
FEV1
Mean (SD) 3.83 (0.54) 4.17 (0.54) 3.01 (1.35) 3.64 (0.68)
ICS dose, μg/d
Median (range) 400 (200-400) 400 (200-1000) 200 (200-480)
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Figure 3 Serum concentration versus time profile of multiple doses of CAT-354 at doses of (A) 1 mg/kg, (B) 5 mg/kg and (C) 10 mg/
kg administered at 28-day intervals by intravenous infusion.
Singh et al. BMC Pulmonary Medicine 2010, 10:3
http://www.biomedcentral.com/1471-2466/10/3
Page 5 of 8
Although assessment of the 10-mg/kg group was diffi-
cult due to the small sample size, the pharmacokinetics
appeared to be proportional to those of lower doses
(Table 2). Clearance (CL) (2.2-2.6 mL/day/kg) and
volume of distribution (Vd) (44-57 mL/kg) were both
low and independent of dose level. The half-life after
the third dose was 14.8-25.1 days.
Cmax and the concentration after 28 days (C28) showed
a small increase with multiple dosing (Table 3). These
small increases were consistent with the calculated accu-
mulation ratio (R0) for AUC(0-t). The mean R0 was 1.58,
1.39 and 1.67 for 1, 5 and 10 mg/kg of CAT-354,
respectively.
Safety Profile
All 23 subjects experienced at least 1 adverse event. The
majority of adverse events were of mild or moderate
intensity and were not considered treatment-related (70
unrelated adverse events). The most common events
were nasopharyngitis (reported by 17 subjects) and
headache (reported by 10 subjects) and were reported
both in subjects receiving CAT-354 and those receiving
placebo (Table 4).
Adverse events that were considered by the investiga-
tor to be possibly related to treatment with CAT-354
were reported by three subjects. One subject experi-
enced mild eczema that started 4 days after the second
dose (1 mg/kg) and recovered after 6 weeks; 1 subject
had a bloated stomach, epigastric discomfort and diar-
rhoea of moderate intensity on the day of the second
dose (5 mg/kg) that lasted 2 days, plus moderate pain in
the infusion arm that recovered on the same day; 1 sub-
ject experienced mild chest tightness on the day of dose
1 (10 mg/kg) that resolved on the same day.
Seven subjects were withdrawn from the study (Figure
2). One of these subjects was withdrawn after a chest
infection that led to an exacerbation of asthma and was
considered a serious adverse event. This occurred 20
days after the first dose (5 mg/kg) and was judged as
unlikely to be related to the study drug. The subject
recovered without obvious sequelae. Four additional sub-
jects were withdrawn because of adverse events assessed
by the investigator as unrelated or unlikely related to the
study drug; 3 of these adverse events were respiratory
tract infections. Two of these subjects received 1 mg/kg,
1 subject received 10 mg/kg and 1 subject received pla-
cebo. Two other subjects withdrew; one was withdrawn
by the investigator because of the need for treatment of a
pre-existing condition, and the other subject withdrew
due to inability to complete the visit schedule.
There were no clinically significant effects for vital
signs, ECG, laboratory or physical examination para-
meters. There was no evidence of dose-related changes
in FEV1, FVC, FEV1/FVC ratio, and % predicted FEV1 of
clinical concern and no increased use of rescue SABA
except for the subject who had an exacerbation of
asthma.
Immunogenicity
There was no evidence of immunogenicity induced by
CAT-354 in any of the samples collected from the sub-
jects enrolled in this study.
Table 2 Pharmacokinetic parameters after a single dose








Cmax (μg/mL) 30.3 (5.2) 157 (34.5) 306 (31.4)
AUC(0-t) (μg.day/mL) 300 (42.0) 1691 (303) 3106 (719)
AUC(0-inf) (μg.day/mL) 428 (83.3) 2314 (393) 3861 (662)
t1/2 (days) 16.6 (2.7) 16.1 (3.6) 11.8 (1.9)
CL* (mL/day/kg) 2.41 (0.5) 2.23 (0.5) 2.64 (0.4)
Vd (mL/kg) 56.7 (8.0) 51.0 (10.4) 44.0 (0.8)
Note: Values are arithmetic mean (SD) after dose 1.
*Corrected for body weight
Table 3 Observed maximum concentration (Cmax) and
concentration after 28 days (C28) following three doses of
CAT-354 (PK population)
CAT-354
1 mg/kg 5 mg/kg 10 mg/kg
Cmax (μg/mL)
Dose 1 30.3 (5.2) [n = 8] 157 (34.5) [n = 8] 306 (31.4) [n = 3]
Dose 2 35.0 (6.8) [n = 7] 161 (32.8) [n = 7] 298 (-) [n = 1]
Dose 3 41.1 (4.8) [n = 6] 179 (25.4) [n = 7] 393 (-) [n = 1]
C28 (μg/mL)
Dose 1 5.3 (1.3) [n = 8] 27.1 (4.9) [n = 7] 40.7 (-) [n = 1]
Dose 2 7.7 (1.6) [n = 6] 36.0 (11.5) [n = 7] 59.4 (-) [n = 1]
Dose 3 8.6 (2.0) [n = 6] 40.6 (12.3) [n = 7] 79.6 (-) [n = 1]
Note: Values are arithmetic mean (SD).
Table 4 Incidence of most common adverse events
(safety population)










Nasopharyngitis 5 (62.5) [6] 7 (87.5)
[10]
2 (66.7) [2] 3 (75.0) [4]
Headache 3 (37.5) [3] 4 (50.0) [6] 1 (33.3) [1] 2 (50.0) [4]
Lower respiratory
tract infection
1 (12.5) [1] 1 (12.5) [1] 0 1 (25.0) [2]
Cough 1 (12.5) [1] 1 (12.5) [1] 0 1 (25.0) [1]
Pharyngolaryngeal
pain
0 1 (12.5) [1] 1 (33.3) [2] 0
Pain 1 (12.5) [1] 1 (12.5) [1] 0 0
Chest discomfort 0 0 1 (33.3) [1] 1 (25.0) [1]
Diarrhoea 1 (12.5) [1] 1 (12.5) [1] 0 0
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Discussion
This study has evaluated the pharmacokinetics and
safety of CAT-354 at three dose levels administered by
intravenous infusion on three occasions at intervals of
28 days. The pharmacokinetics were linear over the
dose range studied. The half-life was found to be
approximately 2-3 weeks, and the accumulation of drug
was low. CAT-354 exhibited an acceptable safety profile
with few adverse events that could have been related to
treatment.
Cmax and AUC demonstrated a good relationship with
dose level, whilst clearance and volume of distribution
were independent of dose level, consistent with linear
pharmacokinetics. The low clearance of CAT-354 (2.2-
2.6 mL/day/kg) was consistent with the expected clear-
ance of an IgG antibody that is not subject to target-
mediated disposition [17]. The observed maximum con-
centration (Cmax) after each dose and 28 days after each
dose (C28) increased by small amounts from dose 1
through dose 2 to dose 3 at all dose levels. The accumu-
lation potential for CAT-354 was low with R0 not much
greater than 1. However, with the observed pharmacoki-
netic characteristics, including low clearance, the drug
remained at measurable concentrations in the serum,
with levels still well above the quantifiable limit when
final samples were taken up to 91 days after the final
dose. The long half-life and low clearance of CAT-354
should maintain exposure to drug over the monthly dos-
ing interval.
CAT-354 demonstrated an acceptable safety profile,
with the majority of adverse events reported not related
to study drug, and most events were of mild to moder-
ate intensity. There were no dose-related adverse events
and no subject experienced a serious adverse event that
was thought to be related to study drug administration.
There were two cases of diarrhoea post-infusion. Diar-
rhoea has been described as part of a constellation of
symptoms that can occur during infusion reactions of
mild intensity secondary to intravenous administration
of antibodies [18]. These kinds of reactions, however,
occurred at the lower doses of CAT-354, diminishing
the likelihood of protein overload as a cause of the
diarrhoea.
Seven subjects withdrew from the study, of which 5
were due to adverse events. Four of these adverse events
were chest infections, with 3 occurring in the active
treatment groups and 1 in the placebo group. It is to be
expected that chest infections will occur in a multiple-
dose study of long duration, and reassuringly there was
no clear pattern for an increase in infections in the
active treatment arms. The overall numbers of infections
was low, and larger studies are needed to confirm the
safety characteristics of this immune-modulating
treatment. In addition, there were no effects of concern
in any vital signs, ECG or laboratory parameters, and
there were no effects of CAT-354 on lung function,
which remained stable throughout the study treatment.
There was no evidence of immunogenicity induced by
CAT-354 in any of the samples collected during the
study. These observations indicate that the doses of
CAT-354 administered in the current study exhibited a
safety profile suitable for further study. Future studies
may also focus on the development of subcutaneous
administration, as this will have practical advantages for
administration.
There have been concerns about potential side effects
of biological approaches to immunomodulation, such
as the use of human monoclonal antibodies. The
adverse event data, lung function, laboratory evalua-
tions and immunogenicity tests in the current study
suggest that CAT-354 can be safely administered in a
repeat dosing schedule at doses up to 10 mg/kg.
Although only 3 subjects received the 10-mg/kg repeat
dose, no additional safety concerns were identified at
this dose compared to the lower doses. Future studies
could test repeated doses up to 10 mg/kg, and the next
step for this drug would be to assess clinical efficacy
such as through a properly powered study to evaluate
pulmonary function. The current study used pulmon-
ary function as a safety measure and was not properly
powered to assess clinical benefits due to the low num-
ber of subjects.
The current study provides a safety assessment of
multiple-dose administration of CAT-354 that supports
further trials, and now efficacy studies are needed to
evaluate the therapeutic potential of this drug. Pitrakinra
is a recombinant IL-4 variant that competitively antago-
nises the IL-4Ra, and therefore interferes with the func-
tion of both IL-4 and IL-13 at the IL-4Ra/IL-13Ra1
receptor complex. This drug has been shown to inhibit
the allergen challenge response in asthma [19]. The rela-
tive contributions of blocking IL-13 as opposed to IL-4
function to these results is not known, although animal
studies suggest that IL-13 plays a dominant role in TH-
2 inflammation [10-14]. Human proof-of-concept stu-
dies using CAT-354 are required to confirm these ani-
mal findings.
Conclusions
The pharmacokinetics following repeat doses of 1 and 5
mg/kg CAT-354 were characterised in this study. The
10-mg/kg treatment group, although of a small sample
size, indicated pharmacokinetics that were broadly pro-
portional to lower doses. The safety profile of CAT-354
observed in this study warrants the conduct of future
studies to evaluate clinical efficacy.
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